Table 2.
Reported bleeding episodes after vaccination against covid-19 with either an mRNA vaccine (mainly Pfizer-Biontech) or an adenovirus-vectored vaccine (Oxford-AstraZeneca).
| mRNA vaccine, dose 1 | mRNA vaccine, dose 2 | AstraZeneca, dose 1 | Crude OR* (95% CI) |
Adjusted OR** (95 %CI) |
|
|---|---|---|---|---|---|
| Number vaccinated | 3416 | 3135 | 5132 | ||
| Skin bleeding, n (%) | 7 (0.2) | 13 (0.4) | 163 (3.2) | 16.0 (7.5–34.1) | 13.9 (6.5–29.7) |
| Nose bleeding, n (%) | 9 (0.3) | 15 (0.5) | 106 (2.1) | 8.0 (4.0–15.8) | 7.0 (3.5–13.9) |
| Gingival bleeding, n (%) | 7 (0.2) | 15 (0.5) | 96 (1.9) | 9.3 (4.3–20.0) | 8.1 (3.7–17.6) |
*
Odds ratio with 95% confidence interval comparing the bleeding after the first dose of the AstraZeneca vaccine to the bleeding after the first dose of the mRNA vaccine.
**
Odds ratio with 95% confidence interval adjusted for age group, sex, chronic disease, ever tested positive for SARS-Cov-2 and occupation, n = 7821 (excluding subjects with missing values for chronic disease and occupation).